Affimed Therapeutics AG (Affimed)

Oncology Corporate Profile

Company Description

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAbĀ® antibody platform. Affimed's product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13).

Website: http://www.affimed.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
AFM13bi-specific tetravalent antibodyHodgkin's LymphomaII
AFM11T-cell receptorAcute Lymphocytic Leukemia (ALL)I
AFM13 (+ PD 1)bi-specific tetravalent antibodyHodgkin's LymphomaIMerck
AFM11T-cell receptorNon-Hodgkin's Lymphoma (NHL)I
AFM13bi-specific tetravalent antibodyT-cell lymphomaI
AFM24EGFRwt receptorHead & Neck cancerPreclinical
AFM24EGFRwt receptorNon Small Cell Lung Cancer (NSCLC)Preclinical

View additional information on product candidates here »

Source: http://www.affimed.com

Recent News Headlines

There are no news items to display